KMDA Kamada Ltd.

6.17
-0.09  -1%
Previous Close 6.26
Open 6.22
Price To Book 2.21
Market Cap 248620631
Shares 40,295,078
Volume 100,140
Short Ratio
Av. Daily Volume 120,236

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
KamRAB
Prophylaxis of rabies disease
Phase 3 trial planned for 2H 2019.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)

Latest News

  1. Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
  2. Kamada announces FDA acceptance of Inhaled AAT program path forward
  3. 5 Stocks With Increasing Cash Flows to Scoop Up Big Gains
  4. Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
  5. Acorda to Gain From Inbrija Sales and Neurological Pipeline
  6. BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
  7. Kamada (KMDA) Stock Sinks As Market Gains: What You Should Know
  8. Tap These 6 Stocks That Flaunt Sizeable Net Profit Margin
  9. PhaseBio Stock Up on Breakthrough Therapy Status for PB2452
  10. Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
  11. Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457
  12. Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
  13. Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study
  14. Kamada (KMDA) Gains But Lags Market: What You Should Know
  15. Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down
  16. Seattle Genetics Closes Enrollment in Cervical Cancer Study
  17. The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
  18. 4 Small Biotech Stocks Likely to Witness More Upside in 2019
  19. Kamada (KMDA) Flat As Market Gains: What You Should Know
  20. Blueprint Medicines Expediates Filings for Key Candidates